Results 31 to 40 of about 766,818 (299)

Programmed death 1 (PD‐1) and ligand (PD‐L1) inhibitors in head and neck squamous cell carcinoma: A meta‐analysis

World Journal of Otorhinolaryngology-Head and Neck Surgery, 2022
Background PD‐1 and PD‐L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC). Methods Systematic review and meta‐analysis of PD‐1 and PD‐L1 inhibitors in HNSCC.
Dylan A. Levy, Jaimin J. Patel, Shaun A. Nguyen, W. Nicholas Jungbauer, David M. Neskey, Ezra E. W. Cohen, Chrystal M. Paulos, John A. Kaczmar, Hannah M. Knochelmann, Terry A. Day   +9 more
doaj   +1 more source

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas [PDF]

Blood, 2018
Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers including hematologic malignancies. This article reviews the landscape of PD-1/programmed death-ligand 1 (PD-L1) expression and current PD-1 blockade immunotherapy trials in B-cell ...
Xu-Monette, Zijun Y, Zhou, Jianfeng, Young, Ken H   +2 more
openaire   +2 more sources

CTLA-4 and PD-1 ligand gene expression in epithelial thyroid cancers [PDF]

, 2018
The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80 and CD86 was evaluated at mRNA level in 94 patients affected ...
Antonelli, Alessandro, Arcieri, Stefano, Baldini, Enke, Barollo, Susi, Carbotta, Giovanni, Catania, Antonio, Fallahi, Poupak, Mian, Caterina, Monti, Massimo, Palmieri, Andrea, Pironi, Daniele, Sorrenti, Salvatore, Tartaglia, Francesco, Tuccilli, Chiara, Ulisse, Salvatore, Vergine, Massimo   +15 more
core   +3 more sources

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)

Frontiers in Cellular and Infection Microbiology, 2019
In the present study, we determined the in vitro characteristics and binding interactions of chicken PD-1 (chPD-1) and PD-L1 (chPD-L1) and developed a panel of specific monoclonal antibodies against the two proteins.
Vishwanatha R. A. P. Reddy, William Mwangi, Yashar Sadigh, Venugopal Nair   +3 more
doaj   +1 more source

Anti-PD-1-Induced Hidradenitis Suppurativa [PDF]

Dermatopathology, 2021
Mucocutaneous adverse events are commonly observed under immune checkpoint inhibitors (ICIs) therapy. Here, we report the case of a 43-year-old male patient with a stage IIIC melanoma disease who developed hidradenitis suppurativa (HS) three months after the beginning of an anti-PD-1 (nivolumab) adjuvant therapy.
Maillard, Alexia, Pastor, Damien, Merat, Rastine   +2 more
openaire   +4 more sources

PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. [PDF]

, 2016
A new approach to the management of non-small-cell lung cancer (NSCLC) has recently emerged that works by manipulating the immune checkpoint controlled by programmed death receptor 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1).
Booton, R, Cane, P, Cree, IA, Gosney, J, Ibrahim, M, Kerr, K, Lal, R, Lewanski, C, Navani, N, Nicholson, AG, Nicolson, M, Summers, Y   +11 more
core   +2 more sources

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade [PDF]

The Journal of Experimental Medicine, 2006
The programmed death (PD)-1–PD-1 ligand (PD-L) pathway, which is part of the B7–CD28 family, consists of the PD-1 receptor and its two ligands PD-L1 and PD-L2. Engagement of PD-1 by its ligands inhibits immune responses, and recent work has shown that PD-1 is highly expressed on exhausted T cells during chronic lymphocytic choriomeningitis virus (LCMV)
Freeman, Gordon J., Wherry, E. John, Ahmed, Rafi, Sharpe, Arlene H.   +3 more
openaire   +2 more sources

Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]

, 2016
BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas, Chmielowski, Bartosz, Crompton, Joseph G, Dry, Sarah, Eilber, Fritz C, Federman, Noah, Jensen, Sarah, Li, Yunfeng, Nelson, Scott, Shurell, Elizabeth, Singh, Arun S, Tumeh, Paul   +11 more
core   +2 more sources

Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells

BMC Cancer, 2020
Background There are many types of therapies for cancer. In these days, immunotherapies, especially immune checkpoint inhibitors, are focused on. Though many types of immune checkpoint inhibitors are there, the difference of effect and its mechanism are ...
Kazushige Yoshida, Masanori Okamoto, Jun Sasaki, Chika Kuroda, Haruka Ishida, Katsuya Ueda, Hirokazu Ideta, Takayuki Kamanaka, Atsushi Sobajima, Takashi Takizawa, Manabu Tanaka, Kaoru Aoki, Takeshi Uemura, Hiroyuki Kato, Hisao Haniu, Naoto Saito   +15 more
doaj   +1 more source

PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

Nature Immunology, 2019
Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is crucial for the development of reversal strategies. In anti-PD-1-resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance, while PD-1 blockade before antigen priming abolished therapeutic outcomes.
Vivek Verma, Rajeev K Shrimali, Shamim Ahmad, Winjie Dai, Hua Wang, Sumin Lu, Rahul Nandre, Pankaj Gaur, Jose Lopez, Moshe Sade-Feldman, Keren Yizhak, Stacey L. Bjorgaard, Keith T. Flaherty, Jennifer A. Wargo, Genevieve M. Boland, Ryan J. Sullivan, Gad Getz, Scott A. Hammond, Ming Tan, Jingjing Qi, Phillip Wong, Taha Merghoub, Jedd Wolchok, Nir Hacohen, John E. Janik, Mikayel Mkrtichyan, Seema Gupta, Samir N. Khleif   +27 more
openaire   +3 more sources